Replimune Group - REPL Stock Forecast, Price & News

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group Stock Performance

NASDAQ:REPL traded up $0.47 on Friday, reaching $20.27. The stock had a trading volume of 164,745 shares, compared to its average volume of 183,596. The stock has a market cap of $999.51 million, a P/E ratio of -8.08 and a beta of 1.98. Replimune Group has a 12-month low of $13.05 and a 12-month high of $35.93. The business's 50-day moving average price is $18.54 and its 200 day moving average price is $17.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 19.46 and a current ratio of 19.79.

Replimune Group (NASDAQ:REPL - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.15). As a group, equities analysts expect that Replimune Group will post -2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Wedbush lowered their target price on Replimune Group from $59.00 to $52.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 24th. Piper Sandler cut their price objective on shares of Replimune Group from $52.00 to $44.00 in a research report on Thursday, May 19th. SVB Leerink decreased their price objective on shares of Replimune Group from $48.00 to $37.00 and set an "outperform" rating for the company in a report on Friday, August 5th. Finally, HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Replimune Group in a research report on Tuesday, May 24th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $46.00.

Insiders Place Their Bets

In related news, insider Pamela Esposito sold 3,507 shares of Replimune Group stock in a transaction on Monday, May 16th. The stock was sold at an average price of $14.59, for a total value of $51,167.13. Following the transaction, the insider now owns 229,402 shares in the company, valued at $3,346,975.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Replimune Group news, CEO Philip Astley-Sparke sold 9,632 shares of Replimune Group stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $14.59, for a total value of $140,530.88. Following the completion of the transaction, the chief executive officer now directly owns 1,401,080 shares in the company, valued at $20,441,757.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Pamela Esposito sold 3,507 shares of the business's stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $14.59, for a total transaction of $51,167.13. Following the transaction, the insider now directly owns 229,402 shares of the company's stock, valued at $3,346,975.18. The disclosure for this sale can be found here. Insiders have sold a total of 22,899 shares of company stock valued at $334,096 in the last quarter. 23.80% of the stock is currently owned by company insiders.